Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study

Inclusion Criteria

• •Patient with diagnosis of moderate-to-severe chronic plaque psoriasis documented in the medical chart.
• •Patient who need systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor. Tildrakizumab must be the anti-IL-23p19 selected therapy before including the patient in the study.
• •Patient aged 18 years or older at the time of patient recruitment.
• •Patient who have provided written informed consent (if required by country regulations).